APA (7th ed.) Citation

Swain, S. M., Tan, A. R., Gianni, L., Kümmel, S., Dang, C. T., Schneeweiss, A., . . . Loibl, S. (2023). Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer. European journal of cancer, 178, . https://doi.org/10.1016/j.ejca.2022.09.024

Chicago Style (17th ed.) Citation

Swain, Sandra M., et al. "Incidence and Severity of Anaphylaxis and Hypersensitivity in Trials of Intravenous Pertuzumab Plus Trastuzumab or the Fixed-dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection for HER2-positive Breast Cancer." European Journal of Cancer 178 (2023). https://doi.org/10.1016/j.ejca.2022.09.024.

MLA (9th ed.) Citation

Swain, Sandra M., et al. "Incidence and Severity of Anaphylaxis and Hypersensitivity in Trials of Intravenous Pertuzumab Plus Trastuzumab or the Fixed-dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection for HER2-positive Breast Cancer." European Journal of Cancer, vol. 178, 2023, https://doi.org/10.1016/j.ejca.2022.09.024.